Perkins A C, Pimm M V, Morgan D A, Wastie M L, Reynolds J R, Baldwin R W
Nucl Med Commun. 1986 Oct;7(10):729-39. doi: 10.1097/00006231-198610000-00003.
Preliminary clinical studies have been carried out to determine whether the monoclonal antibody 791T/36 would localize in primary lung cancer to an extent sufficient for external detection by gamma scintigraphy. Radiolabelling of the antibody with 131I permitted visualization of three out of eight (38%) tumours using planar imaging with 99Tcm-labelled blood pool subtraction. Radiolabelling of the same antibody with 111In permitted visualization of tumour uptake in nine out of 13 (69%) tumours, without the need for image subtraction. Single photon emission computed tomography (SPECT) studies of seven patients demonstrated concentration of 111In-labelled antibody at the tumour site in each case, four of which were visualized on the planar images. The present study demonstrates localization of the 791T/36 antibody in primary lung carcinoma and confirms the superiority of 111In over 131I as a radiolabel for antibody imaging, especially when emission tomography is performed. These data indicate that further work will be required to determine whether this antibody will be a suitable carrier for cytotoxic agents in the therapy of lung cancer.
已经开展了初步临床研究,以确定单克隆抗体791T/36在原发性肺癌中的定位程度是否足以通过γ闪烁显像进行外部检测。用131I对抗体进行放射性标记,通过99Tcm标记的血池减影平面显像,在八例肿瘤中有三例(38%)可见肿瘤。用111In对同一抗体进行放射性标记,在13例肿瘤中有9例(69%)可见肿瘤摄取,无需图像减影。对7例患者进行的单光子发射计算机断层扫描(SPECT)研究表明,每例患者肿瘤部位均有111In标记的抗体聚集,其中4例在平面图像上可见。本研究证明了791T/36抗体在原发性肺癌中的定位,并证实111In作为抗体显像的放射性标记优于131I,尤其是在进行发射断层扫描时。这些数据表明,需要进一步开展工作以确定该抗体是否将成为肺癌治疗中细胞毒性药物的合适载体。